Get the Stockscreener App
0.00
0.00%
0.00
Vitro Biopharma, Inc. stock is traded at $0.00, with a volume of 0.
It is up +0.00% in the last 24 hours and up +0.00% over the past month.
Vitro Biopharma is an innovative biotechnology company focused on developing Wharton's jelly-derived cell therapies for autoimmune diseases and inflammatory disorders. Their goal is to become a leader in developing differentiated product candidates in a rapid and efficient manner for the immunology and inflammatory market.
See More
Previous Close:
$0.00
Open:
$0
24h Volume:
0
Relative Volume:
Market Cap:
$N/A
Revenue:
$1.65M
Net Income/Loss:
$-5.91M
P/E Ratio:
0.00
EPS:
-0.1707
Net Cash Flow:
$-3.03M
1W Performance:
+0.00%
1M Performance:
+0.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$0.00
Vitro Biopharma, Inc. Stock (VTRO) Company Profile
Name
Vitro Biopharma, Inc.
Sector
Industry
Phone
(720) 859-4120
Address
4621 TECHNOLOGY DRIVE, GOLDEN
Compare VTRO vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VTRO
Vitro Biopharma, Inc.
|
0.00 | 0 | 1.65M | -5.91M | -3.03M | -0.1707 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Vitro Biopharma, Inc. Stock (VTRO) Latest News
Vitro Biopharma, Inc. Reports Earnings Results for the Full Year Ended October 31, 2025 - marketscreener.com
Best Biotech Stocks of 2026 and How to Invest in Them - The Motley Fool
Reviewing Rein Therapeutics (NASDAQ:RNTX) and Vitro Diagnostics (OTCMKTS:VODG) - Defense World
Financial Contrast: Imunon (NASDAQ:IMNN) vs. Vitro Diagnostics (OTCMKTS:VODG) - Defense World
What Stem Cell Clinics Do You Trust? - BioInformant
10 cultured meat companies driving sustainable food in 2025 - Labiotech.eu
Vitro Biopharma's AlloRx Stem Cell Therapy Featured in New York Times Article on Health Secretary Kennedy's Vision for Expanding Access to Regenerative Medicine - ACCESS Newswire
Vitro Biopharma Receives FDA Authorization to Conduct a Clinical Trial Using AlloRx Stem Cells(R) to Treat COVID-19 - ACCESS Newswire
Dealmaking Quarterly Statistics, Q4 2024 - Citeline News & Insights
Stem Cell Therapy for the Coronavirus COVID-19 Pandemic - ACCESS Newswire
Akoya Biosciences Selects Argonaut Manufacturing Services as IVD Manufacturing Partner - Business Wire
Closing the women’s health gap: Biopharma’s untapped opportunity - McKinsey & Company
Layoffs Continued Across Biopharma in 2024 - BioSpace
In Vitro Diagnostics (IVD) Market Size to Surpass USD 157.56 Billion by 2034 - BioSpace
Swiss biotech going strong in 2024: 18 companies to put on your radar - Labiotech.eu
Dealmaking Quarterly Statistics, Q2 2022 - insights.citeline.com
Top 5 In-Vitro Diagnostics [IVD] Companies, Worldwide by 2024 - Fortune Business Insights
A biotech working on a new approach to IVF raises $33M in fresh funding - BioPharma Dive
New In Vitro Data Showing Matinas BioPharma’s LNC Platform - GlobeNewswire
GenScript Biotech Corporation Announces Self-Amplifying RNA Synthesis Service for Advanced Therapeutic Applications - BioSpace
FDA defends lab test rule, as critics fear industry upheaval - BioPharma Dive
ProteoMixture: A cell type deconvolution tool for bulk tissue proteomic data - ScienceDirect.com
Vitro Biopharma adds Crown Resorts legal, compliance chief to board - Compliance Week
EDGAR Filing Documents for 0001493152-24-004779 - SEC.gov
Pharmaceutical Industry Mergers & Acquisitions Roundup - Contract Pharma
SIRION Biotech - Pharmaceutical Technology
Vitro Biopharma, Inc. Announces Chief Financial Officer Changes - marketscreener.com
Kirk Cousins travels to Caribbean for stem cell treatment - kare11.com
Tickers - Finansavisen
In Vitro Fertilization (IVF) Market Size & Share to Surpass $1296.47 Mn by 2030 | Vantage Market Research - Yahoo Finance
IPO Update: Vitro Biopharma Aims For $10 Million U.S. IPO (VTRO) - Seeking Alpha
VTRO IPO NewsStem cell biotech Vitro Biopharma sets terms for $10 million IPO - renaissancecapital.com
Vitro Biopharma, Inc. announced a financing transaction - marketscreener.com
Global Stem Cells Market Research Report 2023: Implications - GlobeNewswire
Vitro Biopharma, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
The Next Normal – The future of biotech: AI-driven drug discovery - McKinsey & Company
GT Biopharma Poster Presentation and Mini Oral Session at - GlobeNewswire
Vitro Biopharma Names Chris Furman Chief Executive Officer - Yahoo Finance
Biotech - McKinsey & Company
Business of Biotechniques 2022 - BioTechniques
Regen BioPharma, Inc. Announces Signing of a Letter of Intent to Acquire an In vitro Diagnostics Start-Up Company Canary Oncoceutics, Inc. Which is Developing Functional Cancer Tests for Personalized Medicine - Stock Titan
Developing A Robust In Vitro Intestinal Model For Preclinical Candidate Screening Of GI Toxicity - Pharmaceutical Online
User - FinancialContent
Vitro Biopharma Receives FDA Authorization to Conduct a Clinical Trial Using AlloRx Stem Cells® to Treat COVID-19 - BioInformant
DVC Stem: Stem Cell Therapy Clinic in the Cayman Islands - BioInformant
In vitro glycoengineeringSuitability for BioPharma manufacturing - Labroots
Critically Ill COVID-19 Patient Successfully Treated with Vitro Biopharma’s AlloRx Stem Cells(R) - BioInformant
Vor Biopharma Raises $110M to Develop Engineered Hematopoietic Stem Cells - BioInformant
Vitro Bio-Pharma 2nd Quarter Ended April 30th 2020 Financial Results of Operations and Shareholder Letter - ACCESS Newswire
VODG), dba Vitro Biopharma, announced its 2nd quarter ended April 30 th 2019 financial results of operations. - SEC.gov
Fujifilm Acquiring Irvine Scientific, IS Japan for $800M, with Cell Culture Media Growth in Mind - Genetic Engineering and Biotechnology News
Vitro Biopharma, Inc. Stock (VTRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.69%
0.68%
Cap:
|
Volume (24h):